Università degli Studi di Torino Prof Valter Maurino Dipartimento di Chimica phone: +39 0116705218 fax: +39 0116707615 Via P. Giuria, 7 10125 Torino Italy e-mail: [email protected] Toxicological evaluation of “PURIFOG Hypo” Page 1/30 Spett.le FONDERIA MESTIERI via Almese, 72 - 10093 Collegno (TO) - IT Tel. +393355977772 / +393494388929 [email protected] Toxicological evaluation of “PURIFOG Hypo” INDEX EXECUTIVE SUMMARY ....................................................................................................................................... 3 PRODUCT TO BE EVALUATED ........................................................................................................................ 3 TOXICOLOGICAL EVALUATION OF “PURIFOG HYPO” ......................................................................... 3 DIPROPYLENE GLYCOL (CAS# 25265-71-8) ........................................................................................................ 4 2, TOXICITY SUMMARY .......................................................................................................................................... 4 3 SKIN IRRITATING AND SENSITIZING EFFECTS ....................................................................................................... 5 3 REPRODUCTIVE AND DEVELOPMENTAL TOXICOLOGY ......................................................................................... 5 3 SKIN, EYE, AND RESPIRATORY IRRITATIONS ........................................................................................................ 6 ETHANOL (CAS # 64-17-5) .................................................................................................................................. 6 TOXICITY SUMMARY ........................................................................................................................................... 6 IRRITATION AND SENSITIZATION EFFECTS ON SKIN ................................................................................................ 7 ORAL ADMINISTRATION ....................................................................................................................................... 8 EFFECTS ON EYES ............................................................................................................................................... 8 INHALATION EFFECTS ......................................................................................................................................... 8 NON HUMAN AND HUMAN ACUTE TOXICITY (ORAL, INHALATION) ......................................................................... 9 2-PROPANOL (ISOPROPANOL, CAS# 67-63-0) ....................................................................................................... 9 TOXICITY SUMMARY ............................................................................................................................................ 9 SKIN, EYE, AND RESPIRATORY IRRITATIONS ....................................................................................................... 10 ORAL ADMINISTRATION ..................................................................................................................................... 10 INHALATION EFFECTS ....................................................................................................................................... 11 SODIUM HYPOCHLORITE (CAS # 7681-52-9)...................................................................................................... 12 Introduction .................................................................................................................................................... 12 Toxicity summary ........................................................................................................................................... 12 Acute Toxicity ................................................................................................................................................. 12 Evidence for Carcinogenicity .......................................................................................................................... 13 Reproductive and Developmental Effects ....................................................................................................... 13 Skin, Eye, and Respiratory Irritations.............................................................................................................. 13 Non-human toxicity summary ........................................................................................................................ 14 POYLETHYLENE GLYCOL 200 (CAS # 25322-68-3) ............................................................................................ 14 32 Toxicity summary ......................................................................................................................................... 15 Skin irritating and sensitizing effects .............................................................................................................. 16 Acute toxicity .................................................................................................................................................. 16 Oral administration ...................................................................................................................................................... 16 Skin application ............................................................................................................................................................ 17 Inhalation route ........................................................................................................................................................... 17 QUATERNARY AMMONIUM COMPOUNDS (CAS# 63449-41-2, 68424-95-3, 68424-85-1) ............................... 17 INTRODUCTION ................................................................................................................................................ 17 TOXICOKINETICS .............................................................................................................................................. 19 Absorption, distribution and elimination ............................................................................................................. 19 Toxicological mechanism ........................................................................................................................................ 19 Codice Fiscale 80088230018 – Partita IVA 02099550010 Università degli Studi di Torino Prof Valter Maurino Dipartimento di Chimica phone: +39 0116705218 fax: +39 0116707615 Via P. Giuria, 7 10125 Torino Italy e-mail: [email protected] Toxicological evaluation of “PURIFOG Hypo” Page 2/30 HUMAN TOXICITY ............................................................................................................................................. 20 Short term/single exposure .................................................................................................................................... 20 Inhalation ............................................................................................................................................................... 20 Oral intake ............................................................................................................................................................. 20 Dermal application skin irritation ........................................................................................................................ 21 Sensitisation .......................................................................................................................................................... 21 Mucous membranes and eye ................................................................................................................................ 21 Long term/repeated exposure ................................................................................................................................ 21 Inhalation ............................................................................................................................................................... 21 Oral intake ............................................................................................................................................................. 22 Dermal application ................................................................................................................................................ 22 Reproductive / developmental effects ................................................................................................................. 22 Genotoxic effects ................................................................................................................................................... 22 Carcinogenic effects .............................................................................................................................................. 22 TOXICITY, ANIMAL DATA ................................................................................................................................... 22 Short term/single exposure .................................................................................................................................... 22 Inhalation ..............................................................................................................................................................